Narrow Indication for Abuse-Deterrent Morphine

The latest opioid approved by FDA will be “expected” to reduce abuse by only one route — injection — in its official labeling.

In a carefully-worded press release, drugmaker Egalet said its extended-release morphine drug Arymo ER “increased resistance to cutting, crushing, grinding or breaking using a variety of tools. Due to its physical and chemical properties, Arymo ER is expected to make abuse by injection difficult.” 1pillst

In an FDA advisory committee meeting last year, participants voted that the drug could deter abuse via the oral, nasal, and intravenous routes of abuse. But there were several reasons only the intravenous route won labeling.

An FDA spokesperson told MedPage Today that MorphaBond, another morphine product, has “marketing exclusivity for labeling describing the expected reduction of abuse of single-entity, extended-release morphine by the intranasal route due to physicochemical properties.” MORE HERE

About RichardB

I am trained and work as a Creative Arts Therapist specializing in group therapy. I have passionately studied, worked, and taught as a hands-on practitioner of the Creative/Expressive and Healing Arts since 1983 integrating various modalities working in a variety of clinical and non-clinical settings. I currently provide Creative Arts and Counseling services to nonprofit agencies as well as occasionally teaching classes and workshops in communities of faith. I use compassion and acceptance to create an environment that is safe and nurturing for all individuals and groups. In my spare time I engage in research and write articles on a variety of subjects, create: poems, music, abstract artwork, and photograph nature.

View all posts by RichardB →